供应athens research & technologyBrand,16-12-030108Item#,Athens Research & Technology；16-12-030108；Cathepsin H, Human Liver

Athens Research & Technology；16-12-030108；Cathepsin H, Human Liver

型号:16-12-030108
联系人:程园
联系电话:18611717737
品牌:athens research & technology

Athens Research & Technology 公司位于美国乔治亚州雅典市，从1986年以来一直于纯化高纯度，高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。我们的常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白，血小板蛋白、转铁蛋白、免疫球蛋白等。二十年多年来，世界各地的研究人员都在使用我们公司的产品。在炎症、状动脉疾病、自身免疫性疾病、癌症、老年痴呆症等等研究的主要科学出版物中都能看到引用我们公司的产品。
我们提供质，可靠的产品和出色的客户服务。我们期待着您的业务。如果需要定制研究服务，Athens Research & Technology 公司能够根据您的项目要求提供的试剂。
产品te色
多种天然提取的人类蛋白质产品；多种兔抗人类蛋白质抗血清。

MW: 28,000
Extinction Coefficient: 1.22

Frozen in 20 mM Na Acetate, pH 4.5, with 1 mM EDTA and 100mM NaCl

Storage: -70°C or lower

Buy Purified Native Human Cathepsin H (CatH), Human Liver.
Bulk Qty Available.

A more basic protein than Cathepsin B or L. Functions as both an aminopeptidase and endopeptidase. Cathepsin H, like cathepsin L and B, is involved in the catabolism of proteins in the lysosomal system.

Activity: greater than 1 unit per mg protein. One unit is defined as the amount of enzyme that hydrolyzes one umole of L-arginine-beta-napthylamide per minute at 40oC using 75 mM potasium phosphate, pH 6.8, with 1 mM EDTA and 3 mM cysteine as the activation buffer.

Prepared from tissue shown to be non reactive for HbsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

Athens Research & Technology products are laboratory reagents and are not to be administered to humans or used for any drug purpose. For research use only.

Product Citation:
Douglas Lu, Weiya, Lydiane Funkelstein, Thomas Toneff, Thomas Reinheckel, Christoph Peters, and Vivian Hook. "Cathepsin H functions as an aminopeptidase in secretory vesicles for production of enkephalin and galanin peptide neurotransmitters." Journal of neurochemistry 122, no. 3 (2012): 512-522.

Ref:
Barrett, A.J. and Kirschke, H. 1981. Methods Enzymol. 80, 535.
Barrett, A.J. 1977. Proteinases in Mammalian Cells and Tissues. (A. Barrett, ed.) 4, 209